Cargando…

Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking

OBJECTIVE: Smoking decreases insulin action and increases the risk of type 2 diabetes in humans. Mechanisms responsible for smoking-induced insulin resistance are unclear. We hypothesized smokers would have increased intramuscular triglyceride (IMTG) and diacylglycerol (DAG) concentration and decrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Bryan C., Perreault, Leigh, Hunerdosse, Devon M., Koehler, Mary C., Samek, Ali M., Eckel, Robert H.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750212/
https://www.ncbi.nlm.nih.gov/pubmed/19581421
http://dx.doi.org/10.2337/db09-0481
_version_ 1782172228785274880
author Bergman, Bryan C.
Perreault, Leigh
Hunerdosse, Devon M.
Koehler, Mary C.
Samek, Ali M.
Eckel, Robert H.
author_facet Bergman, Bryan C.
Perreault, Leigh
Hunerdosse, Devon M.
Koehler, Mary C.
Samek, Ali M.
Eckel, Robert H.
author_sort Bergman, Bryan C.
collection PubMed
description OBJECTIVE: Smoking decreases insulin action and increases the risk of type 2 diabetes in humans. Mechanisms responsible for smoking-induced insulin resistance are unclear. We hypothesized smokers would have increased intramuscular triglyceride (IMTG) and diacylglycerol (DAG) concentration and decreased fractional synthesis rate (FSR) compared with nonsmokers. RESEARCH DESIGN AND METHODS: Nonsmokers (n = 18, aged 20 ± 0.5 years, BMI 22 ± 0.4 kg/m(2), body fat 20 ± 2%, 0 cigarettes per day) and smokers (n = 14, aged 21 ± 0.7 years, BMI 23 ± 0.4 kg/m(2), body fat 20 ± 3%, 18 ± 0.7 cigarettes per day) were studied in a fasted condition after a standardized diet. [U-(13)C]palmitate was infused during 4 h of rest followed by a skeletal muscle biopsy and intravenous glucose tolerance test. RESULTS: Smokers were less insulin sensitive (S(i)) compared with nonsmokers (S(i) 5.28 ± 0.5 nonsmokers vs. 3.74 ± 0.3 smokers 10(−4) · μU(−1) · ml(−1), P = 0.03). There were no differences in IMTG or DAG concentration (IMTG 24.2 ± 3.4 nonsmokers vs. 27.2 ± 5.9 smokers μg/mg dry wt, DAG 0.34 ± 0.02 nonsmokers vs. 0.35 ± 0.02 smokers μg/mg dry wt) or IMTG FSR between groups (0.66 ± 0.1 nonsmokers vs. 0.55 ± 0.09 smokers %/hr). Intramuscular lipid composition was different, with increased percent saturation of IMTG (32.1 ± 1.2 nonsmokers vs. 35.2 ± 1.0 smokers %, P = 0.05) and DAG (52.8 ± 1.7 nonsmokers vs. 58.8 ± 2.2 smokers %, P = 0.04) in smokers. Smokers had significantly decreased peroxisome proliferator–activated receptor-γ (1.76 ± 0.1 nonsmokers vs. 1.42 ± 0.11 smokers arbitrary units [AU], P = 0.03) and increased monocyte chemotactic protein-1 (3.11 ± 0.41 nonsmokers vs. 4.83 ± 0.54 smokers AU, P = 0.02) mRNA expression compared with nonsmokers. We also found increased insulin receptor substrate-1 Ser(636) phosphorylation in smokers compared with nonsmokers (0.73 ± 0.08 nonsmokers vs. 1.14 ± 0.09 smokers AU, P = 0.002). CONCLUSIONS: These data suggest: 1) IMTG concentration and turnover are not related to alterations in insulin action in smokers compared to nonsmokers, 2) increased saturation of IMTG and DAG in skeletal muscle may be related to insulin action, and 3) basal inhibition of insulin receptor substrate-1 may decrease insulin action in smokers.
format Text
id pubmed-2750212
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-27502122010-10-01 Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking Bergman, Bryan C. Perreault, Leigh Hunerdosse, Devon M. Koehler, Mary C. Samek, Ali M. Eckel, Robert H. Diabetes Original Article OBJECTIVE: Smoking decreases insulin action and increases the risk of type 2 diabetes in humans. Mechanisms responsible for smoking-induced insulin resistance are unclear. We hypothesized smokers would have increased intramuscular triglyceride (IMTG) and diacylglycerol (DAG) concentration and decreased fractional synthesis rate (FSR) compared with nonsmokers. RESEARCH DESIGN AND METHODS: Nonsmokers (n = 18, aged 20 ± 0.5 years, BMI 22 ± 0.4 kg/m(2), body fat 20 ± 2%, 0 cigarettes per day) and smokers (n = 14, aged 21 ± 0.7 years, BMI 23 ± 0.4 kg/m(2), body fat 20 ± 3%, 18 ± 0.7 cigarettes per day) were studied in a fasted condition after a standardized diet. [U-(13)C]palmitate was infused during 4 h of rest followed by a skeletal muscle biopsy and intravenous glucose tolerance test. RESULTS: Smokers were less insulin sensitive (S(i)) compared with nonsmokers (S(i) 5.28 ± 0.5 nonsmokers vs. 3.74 ± 0.3 smokers 10(−4) · μU(−1) · ml(−1), P = 0.03). There were no differences in IMTG or DAG concentration (IMTG 24.2 ± 3.4 nonsmokers vs. 27.2 ± 5.9 smokers μg/mg dry wt, DAG 0.34 ± 0.02 nonsmokers vs. 0.35 ± 0.02 smokers μg/mg dry wt) or IMTG FSR between groups (0.66 ± 0.1 nonsmokers vs. 0.55 ± 0.09 smokers %/hr). Intramuscular lipid composition was different, with increased percent saturation of IMTG (32.1 ± 1.2 nonsmokers vs. 35.2 ± 1.0 smokers %, P = 0.05) and DAG (52.8 ± 1.7 nonsmokers vs. 58.8 ± 2.2 smokers %, P = 0.04) in smokers. Smokers had significantly decreased peroxisome proliferator–activated receptor-γ (1.76 ± 0.1 nonsmokers vs. 1.42 ± 0.11 smokers arbitrary units [AU], P = 0.03) and increased monocyte chemotactic protein-1 (3.11 ± 0.41 nonsmokers vs. 4.83 ± 0.54 smokers AU, P = 0.02) mRNA expression compared with nonsmokers. We also found increased insulin receptor substrate-1 Ser(636) phosphorylation in smokers compared with nonsmokers (0.73 ± 0.08 nonsmokers vs. 1.14 ± 0.09 smokers AU, P = 0.002). CONCLUSIONS: These data suggest: 1) IMTG concentration and turnover are not related to alterations in insulin action in smokers compared to nonsmokers, 2) increased saturation of IMTG and DAG in skeletal muscle may be related to insulin action, and 3) basal inhibition of insulin receptor substrate-1 may decrease insulin action in smokers. American Diabetes Association 2009-10 2009-07-08 /pmc/articles/PMC2750212/ /pubmed/19581421 http://dx.doi.org/10.2337/db09-0481 Text en © 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Article
Bergman, Bryan C.
Perreault, Leigh
Hunerdosse, Devon M.
Koehler, Mary C.
Samek, Ali M.
Eckel, Robert H.
Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title_full Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title_fullStr Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title_full_unstemmed Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title_short Intramuscular Lipid Metabolism in the Insulin Resistance of Smoking
title_sort intramuscular lipid metabolism in the insulin resistance of smoking
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750212/
https://www.ncbi.nlm.nih.gov/pubmed/19581421
http://dx.doi.org/10.2337/db09-0481
work_keys_str_mv AT bergmanbryanc intramuscularlipidmetabolismintheinsulinresistanceofsmoking
AT perreaultleigh intramuscularlipidmetabolismintheinsulinresistanceofsmoking
AT hunerdossedevonm intramuscularlipidmetabolismintheinsulinresistanceofsmoking
AT koehlermaryc intramuscularlipidmetabolismintheinsulinresistanceofsmoking
AT samekalim intramuscularlipidmetabolismintheinsulinresistanceofsmoking
AT eckelroberth intramuscularlipidmetabolismintheinsulinresistanceofsmoking